Navigation Links
PharmAthene Closes Acquisition of Avecia Biodefense Vaccines Business Unit
Date:4/2/2008

exclusively to Avecia's vaccines business, including the intellectual property rights associated with its rPA anthrax vaccine and plague vaccine as well as certain government contracts related to such products having an estimated value of approximately $60 million. Approximately 50 employees from Avecia's vaccines operations have transferred to PharmAthene in connection with the transaction.

In consideration for these assets, PharmAthene has paid Avecia a cash payment of $10 million, which is subject to a post-closing working capital adjustment, and will pay an additional $7 million within eighteen months from the closing date. In addition, Avecia will be eligible to receive milestone payments totaling up to $23 million in the aggregate, contingent upon the achievement of certain milestones related to the award of contracts for development and procurement of Avecia's vaccine products by the U.S. government, and potentially royalties if certain sales levels are achieved.

In connection with the acquisition, the parties have also entered into various agreements for the transitional and longer-term supply of facilities, support and services by Avecia to PharmAthene. Among these agreements are a Master Services Agreement pursuant to which Avecia has agreed to provide process development, analytical development, production, disposition, and stability testing of vaccines for PharmAthene. Under a Supply Agreement, Avecia has agreed to manufacture and supply to PharmAthene its requirements for the rPA anthrax and plague vaccines.

On March 28, 2008, Avecia received a letter from the Defence Science and Technology Laboratory, a branch of the UK Ministry of Defence, advising Avecia of the recent resource allocation decision of the US Department of Defense (DoD) that the DoD had decided not to fund Avecia's plague vaccine candidate beyond the current contractual commitments. Based on this development, the parties agreed to amend the sale and purchase agreeme
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PharmAthene Reports Year-End 2007 Financial Results
2. Department of Defense Awards $5.8 Million Contract Modification Providing Additional Funding for PharmAthenes Protexia(R) Program
3. PharmAthene Year-End 2007 Earnings Conference Call and Webcast Scheduled for Monday, March 31, 2008
4. PharmAthene to Delay Release of Full Year 2007 Financial Results
5. PharmAthene Signs Definitive Agreement to Acquire Biodefense Vaccines Business From Avecia
6. PharmAthene to Present at the Cowen and Company 28th Annual Health Care Conference
7. PharmAthene Completes Pharmacokinetic Studies of Protexia(R); Program on Target for IND Filing in 2008
8. PharmAthene Enhances Executive Leadership Team and Appoints Joan Fusco, Ph.D. Senior Vice President of Operations
9. PharmAthene to Present at the BIO CEO & Investor Conference 2008
10. Delaware Court Denies Motion by SIGA Technologies Seeking to Dismiss PharmAthenes Legal Action in Breach of Contract Lawsuit Against SIGA
11. PharmAthene Named as Contractor in $13.9 Million Award Notice Published by the Department of Health and Human Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... September 30, 2014 SoundConnect, ... collaboration company is dedicated to supporting business communication ... Julie Power, a carrier services ... collaboration solutions stays connected and productive at all ... increased movement of businesses to cloud communications services. ...
(Date:9/30/2014)... On September 11, Pharma IQ conducted an interview with ... that he will lead on “Stem Cells” at the ... in London. In the interview posted online ... to several questions on the current state of technologies for ... and future trends in the use of stem cells for ...
(Date:9/30/2014)... New Jersey (PRWEB) September 30, 2014 ... it has been chosen by the Parenteral Drug ... (November 18 and 19, 2014) on container closure integrity ... container closure integrity test methods and philosophies detailed in ... – Integrity Evaluation. The course will span ...
(Date:9/30/2014)... Pittsburgh PA (PRWEB) September 30, 2014 ... Nurses ( IACRN), a non-profit organization based ... Clinical Research Excellence and Safety (ACRES), a ... of a strategic alliance agreement, setting the stage ... is to enhance clinical research quality and safety ...
Breaking Biology Technology:SoundConnect Expands Carrier Services Division 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 2Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 3Adult Stem Cell Technology Center, LLC Director James L. Sherley Discusses Stem Cell Toxicology 4Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 2Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 3Whitehouse Laboratories to Partner with PDA for Educational Course on Container Closure Integrity Testing 4IACRN and ACRES to Support Clinical Research Nurses 2IACRN and ACRES to Support Clinical Research Nurses 3
... Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today ... study of single-agent carfilzomib, a next generation proteasome inhibitor, ... achieved an overall response rate (ORR) (partial response or ... response (DOR) of 8.3 months in patients who entered ...
... show scientists the way to make batches of nanotubes of ... Physical Review Letters unveils an elegant formula by ... the energy of a piece of graphene cut at any ... materials science and of chemistry, said this alone is significant ...
... 6 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE Amex: ... the first 60 patients enrolled in the Phase I/II trial ... reported today in an oral presentation at the 52nd American ... Florida. "Anemia is the most serious symptom associated ...
Cached Biology Technology:Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 2Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 3Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 4Onyx Pharmaceuticals Announces Positive Complete Results From Carfilzomib Phase 2b Study 5Pure nanotube-type growth edges toward the possible 2Pure nanotube-type growth edges toward the possible 3YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 2YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 3YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 4YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 5YM BioSciences Reports Positive Interim Data Including Substantial Anemia Response from Phase I/II Trial of JAK1/JaK2 Inhibitor CYT387 6
(Date:9/29/2014)... PULLMAN, Wash. Scientists at Washington State University ... specifically, Granny Smith apples may help prevent ... be the first to assess these compounds in ... in October,s print edition of the journal ... apples are a good source of these nondigestible ...
(Date:9/29/2014)... decades, planetary geologists have speculated that glaciers might ... chasm that constitutes the Grand Canyon of Mars. ... might have been carved by past glaciers as ... have remained highly controversial and contested. , ... and the Freie Universitaet Berlin has identified what ...
(Date:9/29/2014)... found that a combination of a real-time feedback system ... of residence resulted in a reduction of 37% in ... were 1360.49 kWh, which is equivalent to a reduction ... weeks. , In contrast, another eight halls, exposed ... alert, resulted in saw a 3.5% reduction in energy ...
Breaking Biology News(10 mins):An apple a day could keep obesity away 2Glaciers in the Grand Canyon of Mars? 2Glaciers in the Grand Canyon of Mars? 3Glaciers in the Grand Canyon of Mars? 4Glaciers in the Grand Canyon of Mars? 5Glaciers in the Grand Canyon of Mars? 6Glaciers in the Grand Canyon of Mars? 7Glaciers in the Grand Canyon of Mars? 8Glaciers in the Grand Canyon of Mars? 9
... NY-- The Damon Runyon Cancer Research Foundation named ... 2008 Fellowship Award Committee review. The recipients ... scientists conducting basic and translational cancer research in ... country. The Fellowship is specifically intended to ...
... is available in French . , McGill ... of the world leading pioneers in green chemistry, an entirely ... toxic, petrochemical-based solvents in favour of basic substances like water ... of the green approach are obvious and significant, but following ...
... Industry scientists and international collaborators have discovered the key ... years cost wheat growers worldwide in excess of AUS$7.8 ... prestigious journal Science , scientists from CSIRO Plant ... and Wheat Improvement Center have identified a wheat gene ...
Cached Biology News:Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators 2Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators 3Damon Runyon Cancer Research Foundation awards prestigious fellowships to 13 top young investigators 4Peptides-on-demand: McGill researcher's radical new green chemistry makes the impossible possible 2Saving wheat crops worldwide 2
Detect and measure levels of mouse IgG3 antibody isotypes quickly and easily....
Request Info...
ExonBio Service provides one-stop recobinant protein shopping from cloning, expression and purification. Price including gene cloning....
... This goat anti-rabbit IgG FITC ... antibody' for immunofluorescent staining on tissues ... antibody is generated in rabbits. It ... controls, such as omitting the primary ...
Biology Products: